Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Irbesartan Intermediates: Irbesartan CAS 138402-11-6 Cyano-Irbesartan CAS 138401-24-8 Trityl Irbesartan CAS 138402-10-5 TTBB CAS 124750-51-2 Irbesartan Side Chain Hydrochloride CAS 151257-01-1| Item | Specifications |
| Appearance | White to Off-White Powder |
| Purity / Analysis Method | >98.0% (HPLC) |
| Loss on Drying | <1.00% |
| Residue on Ignition | <0.50% |
| Single Impurity | <1.00% |
| Total Impurities | <2.00% |
| Heavy Metals | <20ppm |
| Infrared Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate / Impurity of Irbesartan (CAS: 138402-11-6) |
Description:
Specifications:
Package & Storage:
| Chemical Name | Trityl Irbesartan |
| Synonyms | Triphenyl Irbesartan; Irbesartan N1-Trityl Impurity; 2-Butyl-3-((2'-(2-trityl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1,3-diazaspiro[4.4]non-1-en-4-one; 2-Butyl-3-[[4-[2-(2-trityl-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one |
| CAS Number | 138402-10-5 |
| CAT Number | RF-PI1893 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C44H42N6O |
| Molecular Weight | 670.84 |
| Density | 1.20±0.10 g/cm3 |
| Boiling Point | 834.6±75.0℃ at 760 mmHg |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Trityl Irbesartan (CAS: 138402-10-5) is an intermediate or impurity of Irbesartan (CAS: 138402-11-6). Irbesartan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. Irbesartan was developed by Sanofi Research (now part of Sanofi-Aventis). It is jointly marketed by Sanofi-Aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.
